Lenvatinib Viatris

Lenvatinib, the active ingredient in Lenvatinib Viatris, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is used to treat certain advanced cancers such as differentiated thyroid carcinoma, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.

GNH USA supplies Lenvatinib Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenvatinib acts on multiple receptor tyrosine kinases that drive tumor growth and angiogenesis.

- Differentiated thyroid carcinoma: slows disease progression and improves survival. - Renal cell carcinoma: inhibits tumor growth and extends progression‑free survival. - Hepatocellular carcinoma: reduces tumor burden and prolongs overall survival. - Endometrial carcinoma: delays disease progression in advanced cases.

Lenvatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypertension - Diarrhea - Fatigue - Nausea - Decreased appetite - Weight loss

Serious or Rare Side Effects: - Arterial thromboembolic events - Severe hepatic impairment - Gastrointestinal perforation or fistula - Significant hemorrhage - Reversible posterior leukoencephalopathy syndrome - Severe proteinuria

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

- Monitor blood pressure: perform regular BP checks and manage hypertension promptly. - Assess liver function: obtain baseline liver enzymes and repeat periodically. - Evaluate for proteinuria: conduct urine protein testing during treatment. - Review cardiac status: baseline ECG and cardiac assessment are recommended. - Avoid in uncontrolled hypertension: ensure BP control before starting. - Store at room temperature: keep in the original pack, protect from moisture and light.

Lenvatinib can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may lower drug exposure. - Anticoagulants (warfarin, DOACs) increase bleeding risk. - Concurrent VEGF pathway inhibitors heighten toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., ketoconazole) may raise plasma levels. - Diuretics can exacerbate hypertension. - Statins metabolized by CYP3A4 require monitoring for muscle toxicity.